 | The 131st Annual Meeting (November 15-19, 2003) of APHA |
|
| The 131st Annual Meeting (November 15-19, 2003) of APHA |
Andrea A Kim, MPH1, Willi McFarland, MD, PhD1, Charlotte K Kent, MPH2, Robert Kohn, MPH2, Ameera Snell2, Brian Louie3, Joe Goldenson, MD4, Jeffrey D Klausner, MD, MPH2, Keith A. Bordelon, MSPH5, and Keith M. Sabin, PhD, MPH5. (1) HIV Seroepidemiology Unit, San Francisco Department of Public Health, 25 Van Ness, Suite 500, San Francisco, CA 94102, 415-597-8169, akim@psg.ucsf.edu, (2) STD Prevention and Control Services, San Francisco Department of Public Health, 1360 Mission St, Ste 401, San Francisco, CA 94103, (3) Public Health Laboratory, San Francisco Department of Public Health, 101 Grove St., 4th Floor, San Francisco, CA 94012, (4) Department of Public Health, San Francisco, Director/Medical Director San Francisco Jail Health Services, 650 5th Street, Suite 309, San Francisco, CA 94107, (5) National Center for HIV, STD, and TB Prevention, Centers for Disease Control and Prevention (CDC), 1600 Clifton Road, MS: E46, Atlanta, GA 30333
Background: Inmates within correctional facilities have high prevalence of hepatitis and HIV infections. We examined the prevalence of hepatitis B virus (HBV), hepatitis C virus (HCV), and co-infections with HIV among persons entering San Francisco’s central intake jail. Methods: From 6/99-12/00, 4,048 residual blood specimens collected for voluntary syphilis screening were tested for HIV after removing identifying information. A stratified random sub-sample of 505 specimens was selected using age, race, sex, and HIV status and tested for HBV surface antigen (HBsAg), HBV surface antibody (anti-HBs), HBV core antibody (anti-HBc), and HCV antibody (anti-HCV) confirmed by RIBA. Data analyses were weighted to adjust for the sampling scheme. Results: Seroprevalence of infections were: HIV 2.6%, HCV 9.2% (anti-HCV+/RIBA+), HBV history 13.9% (anti-HBc+/HBsAg), and chronic HBV 2% (anti-HBc+/HBsAg+); 17% exhibited evidence of HBV vaccination (anti-HBc-/anti-HBs+). HIV/HCV co-infection was 0.9%; HIV/chronic HBV co-infection was 0.3%. Older persons, injection drug users, and those reporting sex with HIV-positive partners were more likely to be co-infected with HIV and HCV. Persons reporting sex with HIV-positive partners were more likely to be co-infected with HIV and chronic HBV. Conclusion: This study provides an opportunity to estimate disease burden and correlates of infection in new arrestees, reflecting risks of acquisition in the outside community. We detected moderate levels of hepatitis infection and low levels of co-infections of HIV, HBV, and HCV. Our data highlight the important opportunity to provide HIV and hepatitis counseling and testing services and HBV vaccination in the correctional setting.
Learning Objectives:
Presenting author's disclosure statement:
I do not have any significant financial interest/arrangement or affiliation with any organization/institution whose products or services are being discussed in this session.